In the phase III CheckMate 214 trial, evaluating nivolumab in combination with ipilimumab versus sunitinib, 91% (1002/1096) of patients in the intention-to-treat (ITT) population had quantifiable tumor tissue available for PD-L1 testing [8]. The gene discussed is CD274; the disease is neoplasm.